Physicians' Academy for Cardiovascular Education

A novel parameter for proximal tubular function in HF

5' education - Aug. 21, 2019 - Lisa Emmens

Adressing the risk of hyperkalemia in HF: is there a sweet spot for potassium binding?

10' education - Aug. 21, 2019 - Prof. van der Meer, MD, PhD

Higher dose of loop diuretics limits uptitration RAASi in HFrEF

5' education - Aug. 20, 2019 - Jozine ter Maaten

Clinical outcomes of GLP-1RA in kidney disease: Current evidence and ongoing trials

10' education - July 12, 2019 - ERA-EDTA 2019 - Frederik Persson, MD

Importance of protection and prevention in diabetic cardiorenal disease

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. John Deanfield, MD

Epigenetic mechanisms targeting ALP: A pathway for prevention of vascular calcification?

10' education - Aug. 7, 2019 - Marta Ruiz-Ortega, PhD

Understanding and managing obesity-related HFpEF

10' education - July 22, 2019 - Milton Packer, MD

Cardiac amyloidosis: an emerging target in HFpEF?

10' education - July 19, 2019 - Prof. van der Meer, MD, PhD

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD

Entry of Lp(a) into the CV arena

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Florian Kronenberg, MD

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD

Lp(a) apheresis and CVD risk modulation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Elisa Waldmann, MD

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD

Assessing individual CV risk and treatment effect with U-Prevent

10' education - July 2, 2019 - Jannick Dorresteijn, MD, PhD

Lp(a) and calcification in aortic stenosis

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Kang He Zheng, MD

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

T2DM & CV outcomes: More than glucose management? - Lessons from GLP-1RA trials

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Stephan Jacob, MD

The future of SGLT2i in HF: Managing patients without T2DM?

10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD

Intensive lifestyle intervention in Look-AHEAD: some T2DM patients benefits, other are harmed

Literature - Aug. 22, 2019 - De Vries TI et al., - Diabetes Care 2019; dc190776

A posthoc, exploratory analysis of Look AHEAD data shows that the treatment effect of an intensive lifestyle intervention on the occurrence of MACE varies greatly between patients.

No improved outcomes with serelaxin in acute HF

Literature - Aug. 22, 2019 - Metra M, et al. - N Engl Med J 2019

In the RELAX-AHF-2 trial, infusion with serelaxin for 48 hours did not result in decrease in CV mortality at 180 days and HF worsening after 5 days compared to placebo in hospitalized acute HF patients.

ApoB/apoA-I ratio associated with risk of aortic valve stenosis in prospective population study

Literature - Aug. 22, 2019 - Zheng KH et al., - J Am Heart Assoc. 2019

Long-term, large study in EPIC-Norfolk cohort finds association of apoB/apoA-I ratio with the risk of aortic valve stenosis incidence, and shows that lp(a) is an independent risk factor for AVS.

A novel parameter for proximal tubular function in HF

5' education - Aug. 21, 2019 - Lisa Emmens
TmP/GFR is a novel parameter for tubular function. Lisa Emmens presents findings of her study on determinants of this parameter and its association with outcomes in HF patients.

ESC HF 2019 TmP/GFR is a novel parameter for tubular function. Lisa Emmens presents findings of her study on determinants of this parameter and its association with outcomes in HF patients.

AHA science advisory on lowering triglycerides with prescription omega-3 fatty acid medications

News - Aug. 21, 2019

A science advisory from the American Heart Association (AHA) stated that prescription omega-3 fatty acid medication reduces triglyceride levels by 20-30% in those with high triglyceride levels.

Adressing the risk of hyperkalemia in HF: is there a sweet spot for potassium binding?

10' education - Aug. 21, 2019 - Prof. van der Meer, MD, PhD
Prof. van der Meer uses a case description to explain the issue of RAASi uptitration in the presence of hyperkalemia in HF. Furthermore, he talks about outcomes and new treatment options in HF patients with hyperkalemia.

Prof. van der Meer uses a case description to explain the issue of RAASi uptitration in the presence of hyperkalemia in HF. Furthermore, he talks about outcomes and new treatment options in HF patients with hyperkalemia.

Primary endpoint met for SGLT2i in HF outcomes trial

News - Aug. 20, 2019

In the phase III DAPA-HF trial, treatment with an SGLT2 inhibitor resulted in reduction in the primary composite endpoint of CV death or worsening of HF in patients with HFrEF compared to placebo.

Higher dose of loop diuretics limits uptitration RAASi in HFrEF

5' education - Aug. 20, 2019 - Jozine ter Maaten
Jozine ter Maaten presents the results of her study on the effects of loop diuretics dosage on the ability to uptitrate RAASi in HFrEF patients and the association of loop diuretics dosage with outcomes.

ESC HF 2019 Jozine ter Maaten presents the results of her study on the effects of loop diuretics dosage on the ability to uptitrate RAASi in HFrEF patients and the association of loop diuretics dosage with outcomes.

Digoxin discontinuation associated with worse outcomes in HFrEF

Literature - Aug. 15, 2019 - Malik A et al. - J Am Coll Cardiol 2019

Discontinuation of digoxin in hospitalized HFrEF patients on more contemporary medical therapy resulted in worse outcomes after 6 months until 4 years after discharge compared to those who stayed on digoxin.

ANGPTL3 antibody halves LDL-c levels in HoFH patients in phase 3 trial

News - Aug. 15, 2019

The ELIPSE HoFH trial met its primary endpoint, showing that evinacumab lowered LDL-c by 49% from baseline in HoFH patients already on other lipid-lowering therapies, including PCSK9 inhibitors.

Artificial intelligence helps pick up AF in ECG acquired during normal sinus rhythm

Literature - Aug. 14, 2019 - Attia Z et al., - The Lancet 2019

An AI model permits point-of-care identification of individuals with a high likelihood of AF, in normal sinus rhythm ECGs, based on subtle findings due to structural changes in the atria.

Clinical outcomes of GLP-1RA in kidney disease: Current evidence and ongoing trials

10' education - July 12, 2019 - ERA-EDTA 2019 - Frederik Persson, MD
Frederik Persson shows evidence of renoprotective effects with GLP-1RA treatment, by discussing various small clinical trials as well as CVOTs with GLP-1RAs.

Frederik Persson shows evidence of renoprotective effects with GLP-1RA treatment, by discussing various small clinical trials as well as CVOTs with GLP-1RAs.